Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reports on five cases of alopecia areata in children and emphasizes the importance of understanding its characteristics for accurate diagnosis in pediatric patients.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that among pediatric patients with alopecia areata, elevated eosinophilic hematological ratios were observed, suggesting these could serve as markers for disease exacerbation and the pathophysiology of the condition.

This article discusses the clinical features, diagnosis, and management of acute radiation syndrome, using a case of a boy exposed to radioactive material in the desert, but reports no new research findings.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.

This review discusses nonsteroidal selective androgen receptor modulators and their potential therapeutic applications but reports no new clinical findings.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This study observed that patients with autism spectrum disorder have a higher risk of developing alopecia areata compared to those without ASD, suggesting a possible link between the two conditions.

This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This review of 32 articles suggests a stronger association between alopecia areata and allergic rhinitis than asthma in both adults and children, indicating a potential Th2-mediated component.

This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

Farudodstat may help treat alopecia areata by protecting hair follicles.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study observed that while dermoscopic features in alopecia areata for dark-skinned individuals align with existing literature, yellow dots appear more frequently and could help in grading disease severity.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This study found that 90% of pediatric patients with alopecia areata had comorbidities, including allergic rhinitis and atopic dermatitis, with localized AA being associated with better treatment outcomes and fewer relapses compared to non-localized forms.

This report presents a case of a 57-year-old woman with APS-4, generalized alopecia, and rheumatoid arthritis, emphasizing the need to screen for other autoimmune disorders in patients with a single organ-specific autoimmune disease.

This article discusses the first international certification examination by the American Board of Hair Restoration Surgery, with no new research findings reported.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This article discusses scalp dermatoscopy and home CI therapy as promising diagnostic and treatment options for alopecia areata but reports no new clinical results.